Technology | November 17, 2008

Parascript Releases AccuDetect 2.0 CAD Algorithms for Assessing Mammograms

November 17, 2008 - Parascript LLC today released its AccuDetect 2.0, the next generation of its computer-aided detection (CAD) algorithms for mammography.

Parascript AccuDetect 2.0 is reportedly more robust with improved performance and increased potential for lowering false-positive rates in detecting suspicious lesions on mammograms. Available for OEM customers interested in reducing false-positive rates of existing CAD systems, AccuDetect is intended to assist radiologists in the early detection of breast cancer during film-based or digital mammography exams.

CAD systems are typically relied upon to identify and highlight hard-to-find features and anomalies on medical images that may be indicative of cancer and bring them to the attention of radiologists. AccuDetect is an enabling technology that reportedly easily integrates with existing analog and digital CAD systems to improve the accuracy of data interpretation. Its primary objective is to enable existing CAD systems to reduce false-positive readings through the utilization of voting methodology in medical imaging.

Parascript AccuDetect 2.0 integrates several proprietary algorithms and sophisticated voting methods to achieve low false-positive rates while maintaining high sensitivity rates. The entire process of applying voting methodology during image processing and analysis is best described as the work of a group of highly skilled experts. Each member has unique skills, expertise, and favored approaches. When they work together as a team, the areas of expertise complement each other, resulting in improved overall performance. Comparing the results of multiple image-recognition processes enables the inherent faults of the procedure to be mitigated, resulting in reduced false-positive and false-negative rates.

For more information: www.parascript.com

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...